Literature DB >> 9002526

Endothelins in the normal and diseased kidney.

D E Kohan1.   

Abstract

Endothelin-1 (ET-1) is a 21-amino acid peptide that potently modulates renal function. ET-1 is produced by, and binds to, most renal cell types. ET-1 exerts a wide range of biologic effects in the kidney, including constriction of most renal vessels, mesangial cell contraction, inhibition of sodium and water reabsorption by the nephron, enhancement of glomerular cell proliferation, and stimulation of extracellular matrix accumulation. ET-1 functions primarily as an autocrine or paracrine factor; its renal effects must be viewed in the context of its local production and actions. This is particularly important when comparing ET-1 biology in the nephron, where it promotes relative hypotension through increased salt and water excretion, with ET-1 effects in the vasculature, where it promotes relative hypertension through vasoconstriction. Numerous studies indicate that ET-1 is involved in the pathogenesis of a broad spectrum of renal diseases. These include those characterized by excessive renal vascular resistance, such as ischemic renal failure, cyclosporine (CyA) nephrotoxicity, radiocontrast nephropathy, endotoxemia, rhabdomyolysis, acute liver rejection, and others. ET-1 appears to play a role in cell proliferation in the setting of inflammatory glomerulonephritides. The peptide also may mediate, at least in part, excessive extracellular matrix accumulation and fibrosis occurring in chronic renal failure, diabetes mellitus, and other disorders. Deranged ET-1 production in the nephron may cause inappropriate sodium and water retention, thereby contributing to the development and/or maintenance of hypertension. Finally, impaired renal clearance of ET-1 may cause hypertension in patients with end-stage renal disease. Many ET-1 antagonists have been developed; however, their clinical usefulness has not yet been determined. Despite this, these agents hold great promise for the treatment of renal diseases; it is hoped that the next decade will witness their introduction into clinical practice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9002526     DOI: 10.1016/s0272-6386(97)90004-4

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  66 in total

1.  Endothelin mediates renal vascular memory of a transient rise in perfusion pressure due to NOS inhibition.

Authors:  X Z Zhang; C Baylis
Journal:  Am J Physiol       Date:  1999-04

Review 2.  Renal ischemia--reperfusion injury: an inescapable event affecting kidney transplantation outcome.

Authors:  R Böhmová; O Viklický
Journal:  Folia Microbiol (Praha)       Date:  2001       Impact factor: 2.099

Review 3.  Bosentan and the endothelin system in congestive heart failure.

Authors:  S H Ellahham; V Charlon; Z Abassi; K A Calis; W K Choucair
Journal:  Clin Cardiol       Date:  2000-11       Impact factor: 2.882

Review 4.  Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure.

Authors:  H Krum; R Denver; A Tzanidis; P Martin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

5.  Identification of two nuclear factor of activated T-cells (NFAT)-response elements in the 5'-upstream regulatory region of the ET-1 promoter.

Authors:  Kevin A Strait; Peter K Stricklett; Rachel M Kohan; Donald E Kohan
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

6.  Increased endothelin activity mediates augmented distal nephron acidification induced by dietary protein.

Authors:  Apurv Khanna; Jan Simoni; Callenda Hacker; Marie-Josée Duran; Donald E Wesson
Journal:  Trans Am Clin Climatol Assoc       Date:  2005

Review 7.  Physiology of endothelin and the kidney.

Authors:  Donald E Kohan; Edward W Inscho; Donald Wesson; David M Pollock
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

Review 8.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 9.  Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.

Authors:  Donald E Kohan; David M Pollock
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

10.  Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention.

Authors:  Dowhan Ahn; Yuqiang Ge; Peter K Stricklett; Pritmohinder Gill; Deborah Taylor; Alisa K Hughes; Masashi Yanagisawa; Lance Miller; Raoul D Nelson; Donald E Kohan
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.